Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy

Danny Khalil,Jedd Wolchok,Taha Merghoub

doi:10.1186/2051-1426-3-s2-p361

Abstract

Meeting abstracts T cell checkpoint blockade and T cell costimulation, two types of immunotherapy undergoing active clinical investigation, have led to improved outcomes for patients with different types of advanced cancer. Given that these approaches can result in durable remissions, there is

Highlights

T cell checkpoint blockade and T cell costimulation, two types of immunotherapy undergoing active clinical investigation, have led to improved outcomes for patients with different types of advanced cancer
Recent data suggest that monoclonal antibodies against tumor antigens generate tumor-specific T cell activity
Our group has demonstrated that TA99, a murine IgG2a monoclonal antibodies (mAbs) against the melanosomal TYRP1 enzyme, can induce tumorspecific T cell responses; and others have shown that breast cancer patients treated with the humanized antiHER2 IgG1 mAb trastuzumab develop tumor-specific T cell responses

Summary

Introduction

T cell checkpoint blockade and T cell costimulation, two types of immunotherapy undergoing active clinical investigation, have led to improved outcomes for patients with different types of advanced cancer. Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) National Harbor, MD, USA. Given that these approaches can result in durable remissions, there is interest in increasing the number of patients who can benefit from them.

Results

Conclusion